Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint

Gossamer Bio, Inc.

PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).
Enrollment in Phase 3 SERANATA (PH-ILD) paused; Company evaluating implications and plans FDA Type C meeting in June 2026.
Implemented reduction in force and cost-containment measures to align resources with near-term priorities.
Cash, equivalents and marketable securities $136.9M at Dec 31, 2025; expected to fund operations into Q1 2027.
Net loss for FY2025 was $170.4M ($0.75 per share) compared to $56.5M ($0.25 per share) in FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.